Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response

Haoran Zhu, Wanrong Zhang, Qingguo Guo, Ruo-Yue Fan, Guangzuo Luo, Ying LiuJournal for ImmunoTherapy of Cancer 2024 · DOI

TL;DR

Researchers have engineered an oncolytic adenovirus (OAd) that acts as a local "factory" for Bispecific T-cell Engagers (BiTEs) targeting B7H3, a protein widely expressed across many cancer types. By delivering the BiTE gene directly into the tumor via a replicating virus, the team successfully activated a potent T-cell response that shrank tumors in mouse models while avoiding the systemic toxicities that have previously hindered B7H3-targeted immunotherapies.

What Problem Does This Paper Address?

Immunotherapy has revolutionized cancer treatment, but two major hurdles remain: systemic toxicity and the "cold" tumor microenvironment (TME).

BiTEs are powerful molecules that act like molecular "matchmakers," with one end binding to a tumor antigen and the other to a T-cell (CD3). This forces T-cells to attack cancer cells regardless of their original specificity. However, BiTEs have very short half-lives in the blood and can cause severe side effects like Cytokine Release Syndrome (CRS) when administered systemically.

Furthermore, many solid tumors are "cold," meaning they lack the T-cell infiltration necessary for BiTEs to work. This paper addresses these gaps by using an oncolytic virus (OV)—a virus that selectively kills cancer cells—to deliver the BiTE. The OV turns the tumor "hot" by causing inflammation and attracting T-cells, while the local production of the BiTE ensures high concentrations at the tumor site and low concentrations in the rest of the body.

Methods

The authors developed a recombinant oncolytic adenovirus named OAd-B7H3-BiTE.

  1. Viral Engineering: They used an Adenovirus Type 5 backbone where the essential replication gene (E1a) is controlled by the human telomerase reverse transcriptase (hTERT) promoter. This ensures the virus only replicates in telomerase-positive cancer cells.
  2. BiTE Construction: They linked a single-chain variable fragment (scFv) targeting B7H3 (derived from the antibody 8H9) to an scFv targeting CD3 (derived from blinatumomab) using flexible linkers.
  3. In Vitro Validation: The team used co-culture assays with human peripheral blood mononuclear cells (PBMCs) and various cancer cell lines to measure T-cell activation (CD69, CD107a expression), cytokine secretion (IFN-γ, IL-2), and direct cytotoxicity.
  4. In Vivo Modeling: They utilized a "humanized" mouse model (M-NSG mice) injected with human PBMCs to provide a functional human immune system, then treated established subcutaneous tumors with the engineered virus.

Datasets

The study relied on several established human cancer cell lines and public databases:

  • Cancer Cell Lines: MGC-803 (gastric cancer), U87 (glioma), SGC-7901 (gastric cancer), SH-SY5Y (neuroblastoma), and Raji (B-cell lymphoma, used as a B7H3-negative control).
  • Public Data: The TIMER2.0 database was used to analyze B7H3 (CD276) expression levels across various human malignancies compared to normal tissues.
  • Patient Samples: Immunohistochemical (IHC) staining was performed on lung, breast, and colon cancer tissues from patients to confirm B7H3 expression patterns.

Key Insights and Ideas

  • B7H3 as a Pan-Cancer Target: The study confirms that B7H3 is highly expressed in a vast array of solid tumors but has low expression in normal tissues, making it an ideal target for "armed" OVs.
  • Turning "Cold" to "Hot": The oncolytic virus doesn't just deliver the BiTE; its replication causes immunogenic cell death. This releases "danger signals" that recruit T-cells to the tumor, providing the "fuel" (T-cells) for the BiTE "engine."
  • Redirecting Anti-Viral Immunity: One of the biggest problems with OV therapy is that the patient’s immune system often attacks the virus instead of the tumor. Because BiTEs activate T-cells in a polyclonal (non-specific) manner, they can actually redirect these anti-viral T-cells to kill the tumor cells instead.
  • Persistent Expression: Unlike systemic BiTEs that are cleared by the kidneys in hours, the OAd-B7H3-BiTE provides a continuous supply of the therapeutic protein as long as the virus is replicating within the tumor.

Key Results

  • Successful Secretion: Western blot analysis confirmed that infected cells successfully produced and secreted the ~57kDa B7H3-BiTE.
  • Potent T-cell Activation: In co-cultures, the BiTE induced significant T-cell clustering, increased cell size, and upregulated activation markers (CD69) and degranulation markers (CD107a).
  • Specific Killing: The OAd-B7H3-BiTE mediated robust killing of B7H3-positive tumor cells (MGC-803 and U87) but had no effect on B7H3-negative Raji cells.
  • In Vivo Efficacy: In humanized mouse models, OAd-B7H3-BiTE treatment led to significantly smaller tumor volumes and weights compared to unarmed OAd or PBS controls.
  • Reduced Exhaustion: Analysis of tumor-infiltrating lymphocytes showed a decrease in exhaustion markers like Tim-3 and PD-1 in the OAd-B7H3-BiTE group.

Limitations and Future Work

  • Species Specificity: The anti-B7H3 portion of the BiTE does not cross-react with mouse B7H3. This means the study could not fully evaluate "on-target, off-tumor" toxicities in normal tissues using a mouse model.
  • Neutralizing Antibodies: Like most adenoviral therapies, pre-existing immunity in humans could limit the virus's effectiveness. The authors suggest that future work could involve shielding the virus in nanoparticles or using different viral capsids.
  • Delivery Route: The study focused on intratumoral injection. While effective for accessible tumors, developing strategies for systemic delivery of these armed OVs remains a major goal for treating metastatic disease.

Summary updated

Abstract

Using an OV for the local expression of B7H3 BiTE maximizes the local concentration of BiTE while reducing systemic exposure. OV also provides a relatively "hot" T-cell immune environment for the function of BiTE. Because of its capacity to activate polyclonal T cells, BiTE has the potential to redirect virus-specific T cells to tumors. Our study provides new opportunities for the exploitation of B7H3-BiTE-armed OVs as therapeutic agents for the treatment of B7H3-positive malignancies.
BibTeX
@article{zhu2024engineered,
  author = {Haoran Zhu and Wanrong Zhang and Qingguo Guo and Ruo-Yue Fan and Guangzuo Luo and Ying Liu},
  title = {{Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response}},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2024-009901},
}
Figure